- Home
- PSNY vs IBRX Comparison
PSNY vs IBRX Comparison
Compare PSNY & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNY
- IBRX
- Stock Information
- Founded
- PSNY 2017
- IBRX 2014
- Country
- PSNY Sweden
- IBRX United States
- Employees
- PSNY N/A
- IBRX N/A
- Industry
- PSNY Auto Manufacturing
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSNY Consumer Discretionary
- IBRX Health Care
- Exchange
- PSNY Nasdaq
- IBRX Nasdaq
- Market Cap
- PSNY N/A
- IBRX 2.4B
- IPO Year
- PSNY N/A
- IBRX N/A
- Fundamental
- Price
- PSNY $0.87
- IBRX $2.42
- Analyst Decision
- PSNY Hold
- IBRX Strong Buy
- Analyst Count
- PSNY 7
- IBRX 5
- Target Price
- PSNY $1.29
- IBRX $11.35
- AVG Volume (30 Days)
- PSNY 4.1M
- IBRX 6.5M
- Earning Date
- PSNY 03-06-2025
- IBRX 05-08-2025
- Dividend Yield
- PSNY N/A
- IBRX N/A
- EPS Growth
- PSNY N/A
- IBRX N/A
- EPS
- PSNY N/A
- IBRX N/A
- Revenue
- PSNY $2,046,740,000.00
- IBRX $14,745,000.00
- Revenue This Year
- PSNY $23.60
- IBRX $621.53
- Revenue Next Year
- PSNY $62.35
- IBRX $163.57
- P/E Ratio
- PSNY N/A
- IBRX N/A
- Revenue Growth
- PSNY N/A
- IBRX 2270.58
- 52 Week Low
- PSNY $0.61
- IBRX $2.28
- 52 Week High
- PSNY $1.94
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- PSNY 26.67
- IBRX 36.34
- Support Level
- PSNY $0.84
- IBRX $2.90
- Resistance Level
- PSNY $1.09
- IBRX $3.26
- Average True Range (ATR)
- PSNY 0.06
- IBRX 0.27
- MACD
- PSNY -0.02
- IBRX -0.03
- Stochastic Oscillator
- PSNY 11.60
- IBRX 3.66
Stock Price Comparison Chart: PSNY vs IBRX
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.